Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $24.40 USD
Change Today -0.80 / -3.17%
Volume 159.4K
SGNT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

sagent pharmaceuticals inc (SGNT) Key Developments

Sagent Pharmaceuticals, Inc. Appoints Michael Logerfo as President

Sagent Pharmaceuticals, Inc. announced that its current EVP and Chief Legal Officer Michael Logerfo has been appointed President, effective April 15, 2015. In his new role as President, Mr. Logerfo will lead the company's Executive Management Committee, will continue to have primary responsibility over the company's strategic business development and legal functions, and will report to the Chairman of the Board. Mr. Logerfo has served as Executive Vice President, Chief Legal Officer and Corporate Secretary of Sagent since March 2012.

Shlomo Yanai Joins Sagent Pharmaceuticals, Inc.'s Board of Directors

Sagent Pharmaceuticals, Inc. announced that Shlomo Yanai has been appointed to its Board of Directors effective April 15, 2015. Mr. Yanai served as President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. from 2007 until 2012.

Sagent Pharmaceuticals, Inc. Announces the Launch of Vancomycin Hydrochloride for Injection, USP

Sagent Pharmaceuticals, Inc. announced the launch of Vancomycin Hydrochloride for Injection, USP, an anti-infective, in a 10 gram preservative-free pharmacy bulk package presentation. The Vancomycin 10 gram presentation is an addition to Sagent's Vancomycin 5 gram pharmacy bulk package offering. According to IMS, for the 12 months ending February 2015, the US market for Vancomycin approximated $196 million of which over 50% of the sales was pharmacy bulk package bottles. As with all products in Sagent's portfolio, Vancomycin features Sagent's PreventIV MeasuresS packaging and labeling, designed to help reduce medication errors.

Sagent Pharmaceuticals, Inc. Reiterates Revenue Guidance for the Fiscal Year of 2015

Sagent Pharmaceuticals, Inc. reiterated revenue guidance for the fiscal year of 2015. The company reiterated its 2015 revenue guidance range of $325 million to $375 million.

Sagent Pharmaceuticals Announces Management Changes

Sagent Pharmaceuticals, Inc. announced that Jeffrey Yordon, Chairman and Chief Executive Officer, has informed the Board of his decision to retire from the Company. He will remain a member of the Board. Frank Kung, Ph.D., a well-regarded industry executive and a member of Sagent's Board since 2006, has been named Chairman. The Board will immediately begin the search for a new CEO. In the interim, the Board has formed an Executive Management Committee to lead the Company. Sagent announced that James Hussey, who served as the Company's President, has decided to leave the Company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGNT:US $24.40 USD -0.80

SGNT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $15.03 USD -0.22
OraSure Technologies Inc $6.63 USD -0.08
Pfizer Ltd/India 2,013 INR -33.10
SciClone Pharmaceuticals Inc $8.73 USD -0.23
Sucampo Pharmaceuticals Inc $19.51 USD -1.58
View Industry Companies
 

Industry Analysis

SGNT

Industry Average

Valuation SGNT Industry Range
Price/Earnings 20.7x
Price/Sales 2.8x
Price/Book 2.9x
Price/Cash Flow 20.3x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAGENT PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.